POET Technologies Regulatory Landscape

Confidence legend: ✓ verified-primary (Federal Register / SEC / OJEU) · ◐ partial / aggregator · ⚠ inferred / estimate.

This page tracks the regulatory regimes that gate POET’s foundry, customer base, M&A pipeline, and SEC reporting status. Every claim is anchored to a primary regulatory document (Federal Register, EU OJ, SAMR notice, Investment Canada Act ruling) where possible; trade-press citations are flagged.

1. China BIS export controls (the dominant regulatory variable for POET)

a. Regulatory baseline

The US Bureau of Industry and Security (BIS) publishes the Export Administration Regulations (EAR) in 15 CFR Parts 730–774. The relevant POET-touching provisions:

EAR § 744.21 — restrictions on certain end-uses (military intelligence, missile-related, weapons of mass destruction). Effective June 29 2020. ✓ Federal Register publication, 85 FR 23459
October 7 2022 advanced-computing rule — controls on advanced computing and supercomputer end-uses; introduced license requirements for ECCN 3A090 / 4A090 items shipped to China-domiciled entities. ✓ Federal Register: 87 FR 62186, Oct 13 2022
October 17 2023 update (“Oct 23 rule”) — closed perceived loopholes from the Oct 22 rule; added performance-density thresholds; expanded entity-list scope. ✓ Federal Register: 88 FR 73424, Oct 25 2023
December 2 2024 amendment — further tightening on HBM and advanced-node logic; added 140 entities to the Entity List; specific HBM rules at ECCN 3A090.b. ✓ Federal Register: 89 FR 96790, Dec 5 2024
January 13 2025 Diffusion Rule (Biden administration) — country-tier framework for AI chip exports; partially rescinded by Trump executive action May 2025. ◐

b. POET’s direct China exposure (post-SPX consolidation)

The 2025-12-31 SPX consolidation (see jv history) means POET now consolidates a wholly-owned PRC subsidiary inside its consolidation perimeter. The relevant exposure points:

SPX is a PRC entity — incorporated in Xiamen, Fujian Province; receives III-V compound-semiconductor inputs from Sanan IC’s Xiamen fab (Sanan IC is a former JV partner). The 20-F discloses SPX’s purpose: “assemble, test, package and sell cost-effective, high-performance optical engines based on POET’s proprietary Optical Interposer platform technology.” ✓ Form 20-F filed 2026-03-31, Item 4.C
POET’s customer base includes China-domiciled module makers — Innolight, Eoptolink, Hisense, Accelink (per industry dynamics). These customers sell completed transceivers to non-China hyperscalers (AWS, Google, Microsoft, Meta).
Sanan IC has not been placed on the BIS Entity List as of 2026-04-29 — verified by inspection of the Entity List published with the Dec-2024 BIS rule 89 FR 96790, Dec 5, 2024. ✓ partial (negative-confirmation — absence verified, but readers should re-validate against the current Entity List PDF on the BIS website at each refresh).

c. Channel-compression risk pathways

Risk pathway A — Foreign Direct Product Rule extension to advanced-modulator-incorporating optical modules:

If BIS were to extend the Foreign Direct Product Rule (FDPR) to cover advanced optical modules incorporating US-designed-or-using-US-software DSPs (Marvell Spica, Broadcom, MaxLinear), Innolight and Eoptolink (China-domiciled customers) would face license-burden delays in selling to US hyperscalers. Compression magnitude could be 20–40% of POET’s serviceable customer revenue in the bear scenario. ⚠ inferred / scenario-flagged

Risk pathway B — Entity-List designation of Sanan IC:

If Sanan IC were designated, POET’s SPX subsidiary would face direct license-burden challenges in receiving III-V wafers from Sanan IC — even though POET-the-Canadian-issuer is not the named entity. Mitigation: the Penang PTM subsidiary (established April 2025) provides an alternative manufacturing path, but any redirection would take 6-12 months to qualify. ⚠ inferred mitigation

Risk pathway C — Cross-border data restrictions on POET-Sanan IP transfer:

The 20-F’s discussion of the December-2024 SPX 24.8% acquisition explicitly notes “use restrictions imposed by the joint venture agreement” (now eliminated by full ownership). However, prospective new IP transfers from POET to SPX or vice versa could fall under outbound-investment review or tech-transfer screening. ⚠ scenario flagged

d. POET’s mitigation posture

The 20-F describes POET’s risk-management posture:

Geographic diversification: PTS (Singapore), POET SZ (Shenzhen), SPX (Xiamen), PTM (Penang) — five operational geographies.
“Fab-light” supply-chain model: POET does not own a wafer fab; III-V devices and silicon waveguides are sourced through external partners. This makes the supply chain more reconfigurable than a vertically-integrated foundry-owning company would be.
Malaysia diversification (PTM, 2025-04-23): Per timeline, the PTM subsidiary in Penang was established explicitly “to manage production of our devices at our contract manufacturers” — providing an alternative manufacturing path outside PRC regulatory perimeter. ✓ Form 20-F filed 2026-03-31, Item 4.A

2. CFIUS / Investment Canada Act / Outbound-Investment review

a. CFIUS posture (POET as US-listed Canadian-domiciled issuer)

The Committee on Foreign Investment in the United States (CFIUS) reviews inbound foreign investment into US businesses for national-security implications under 50 U.S.C. § 4565 (codified at 31 CFR Part 800).

POET-specific exposure:

POET is Canadian-domiciled, US-listed — not a US business per CFIUS definitions, so direct CFIUS jurisdiction over POET as a target does NOT apply.
However, any US-domiciled company POET acquires would trigger CFIUS review, with POET’s PRC subsidiary (SPX) treated as a foreign-control consideration in the analysis.
Conversely, a hypothetical foreign-acquirer’s purchase of POET would not trigger CFIUS unless POET owns specific US-located critical-technology assets. POET’s California-based operations (per the 20-F’s “operations in California” reference) are limited to small office/engineering facilities, unlikely to hit CFIUS triggers. ⚠

b. Investment Canada Act (Canadian-side review of POET acquisitions)

The Investment Canada Act (R.S.C. 1985, c. 28 (1st Supp.)) requires review of foreign-investor acquisitions of Canadian businesses. POET-specific implications:

A foreign-acquirer purchase of POET would trigger Investment Canada Act review.
The enterprise value threshold for non-WTO investors as of January 1, 2026 is approximately CAD$1.387 billion (adjusted annually for inflation per the Investment Canada Act Threshold Reference). ◐
For a “WTO investor” acquiring direct control of a Canadian non-cultural business, the threshold is approximately CAD$1.387 billion as well (the thresholds have aligned post-2024). ◐
POET’s market cap (~$1.2B fully diluted as of April 2026) approaches but is below the threshold; foreign-acquirer transactions of POET could trigger the simpler “notification” requirement rather than the more onerous “review” process. ⚠
National security review under Investment Canada Act § 25.3 has no enterprise-value threshold and applies to all transactions. POET’s PRC subsidiary (SPX) plus its silicon-photonics technology designation in the AI-infrastructure category would likely trigger national-security review under any foreign-acquirer scenario.

c. US Outbound Investment Rule (POET is exempt)

The Biden administration’s Outbound Investment Rule (Executive Order 14105, August 9 2023; final Treasury rule effective January 2 2025) covers US-outbound investment into China, Hong Kong, Macao for specific technology categories. POET is Canadian-domiciled; the rule does not directly apply to POET-the-issuer. ✓ Treasury final rule, 89 FR 90398, Nov 15 2024

However, US-citizen / US-resident shareholders of POET who hold positions in POET’s PRC subsidiary (SPX) indirectly via POET equity could theoretically face outbound-investment-rule scrutiny if Treasury were to extend interpretation to include indirect ownership through Canadian-listed companies. Currently no such interpretive guidance exists. ⚠

3. Foreign-private-issuer status renewal risk

a. The annual FPI determination

POET’s FPI status under SEC rules is re-tested annually on June 30 (the last business day of the second fiscal quarter). The next determination is 2026-06-30. ✓ Form 20-F filed 2026-03-31, Item 3.D

Maintaining FPI status requires either:

(a) Majority of common shares owned of record by non-US persons; OR
(b) Majority of executive officers and directors are not citizens/residents of the US; AND >50% of assets located outside the US; AND business administered principally outside the US.

b. Why POET’s FPI status is at risk

The 20-F’s Item 3.D risk factor flags the issue explicitly: “As a result of the Company’s delisting of its common shares from the TSX Venture Exchange in 2024, resulting in Nasdaq being the sole stock exchange on which the common shares can be publicly traded and subsequent capital raises involving primarily U.S. investors, the Company may lose its status as a foreign private issuer in the future.” ✓ Form 20-F filed 2026-03-31, Item 3.D — direct quote

Three pressure factors:

TSXV delisting (2024) — eliminated the Canadian-based trading venue, shifting POET’s investor base toward US holders.
2025 capital raises — $293M net raised, “primarily U.S. investors” per the 20-F’s risk-factor language. The October 2025 brokered registered direct ($150M at $7.25) was structured for the US institutional market specifically.
January 2026 follow-on — additional ~$143.6M takedown via 424B5 (per timeline) further skews the shareholder mix toward US holders.

c. SEC concept release (June 4, 2025) — additional FPI tightening

The 20-F also notes: “On June 4, 2025, the SEC published a concept release soliciting public comment on whether to amend the eligibility criteria for foreign private issuer status. The concept release outlines several potential approaches to narrow foreign private issuer eligibility, including updating the existing shareholder and business contacts tests, adding minimum non-U.S. trading volume requirements or requiring issuers to have their securities listed on a non-U.S. stock exchange.” ✓ Form 20-F filed 2026-03-31, Item 3.D — direct quote

If the SEC adopts any of those approaches in 2026, POET’s FPI status could be lost regardless of the shareholder-mix test outcome.

d. What happens if POET loses FPI status

If POET fails the FPI determination (likely on the 2026-06-30 test or the next 2027-06-30 test):

Reporting cadence shift: Form 10-K (annual), Form 10-Q (quarterly), Form 8-K (current report) replace Form 20-F + Form 6-K.
Section 16 applies: Officers, directors, 10% holders must file Form 4 within 2 business days of insider transactions.
Reg FD applies: Selective disclosure prohibited; conference-call materials and earnings guidance disclosed simultaneously to the public.
DEF 14A required: Proxy-statement disclosures replace the 20-F Item 6 + management information circular bundle.
**Sarbanes-Oxley Section 404(b) **: External auditor attestation on internal controls becomes required (currently POET as a smaller reporting company is exempt; ⚠ status would change).

The estimated incremental annual cost of FPI-loss compliance is in the $2-5M range for a company POET’s size — meaningful but not capital-structure-altering. ⚠ industry consensus / no specific POET disclosure

4. CHIPS Act and dual-use considerations

The CHIPS and Science Act (Public Law 117-167, signed August 9, 2022) provides US government incentives for semiconductor manufacturing in the United States. POET-specific implications:

POET is Canadian-domiciled with no US wafer-fab footprint. POET is not eligible for direct CHIPS Act manufacturing-incentive grants (those flow to US-based fab operators).
POET’s California-based operations could in principle qualify for CHIPS Act R&D / workforce-development incentives, but POET has not publicly disclosed any CHIPS Act application or award. ⚠
Dual-use export-control implications: CHIPS Act § 4651 imposes “guardrails” on recipients of CHIPS Act funding restricting expansion of semiconductor manufacturing in “covered countries” (China, Russia, North Korea, Iran). POET’s PRC subsidiary (SPX) does NOT receive CHIPS Act funding, so the guardrails do not apply directly. ✓

For the broader US-China advanced-semiconductor competition framing of the CHIPS Act, see Section 1 above (BIS export controls).

5. EU Dual-Use Export framework (limited POET exposure)

The EU Dual-Use Regulation (EU 2021/821, effective September 9 2021) governs export of dual-use items (civilian + military potential) from EU member states to non-EU countries. POET-specific exposure:

POET has no EU-domiciled subsidiaries as of 2026-04-29.
POET’s DenseLight UK Ltd. subsidiary (formerly active under BB Photonics) was dissolved 2020-10-06. ✓ Form 20-F filed 2026-03-31, Item 4.C
POET has European customers (potentially) but does not produce / export from within the EU. EU-Dual-Use compliance is therefore a customer-side concern (POET’s EU module-maker customers must comply when re-exporting), not POET’s direct compliance burden.

6. Summary regulatory exposure matrix

Regulatory regime	POET direct exposure	POET indirect exposure	Mitigation status
US BIS Export Controls	Medium — SPX is a PRC subsidiary	High — China-domiciled module-maker customers (Innolight, Eoptolink, Hisense) face BIS pressure	Penang PTM provides alternative manufacturing path
CFIUS (US inbound review)	Low — Canadian-domiciled, no US critical-tech	Medium — would matter on any future US-target acquisition	N/A
Investment Canada Act	High — would gate any foreign acquirer of POET	N/A	N/A
US Outbound Investment Rule	None — POET is Canadian	Low — US holders of POET equity are not direct outbound-investors	N/A
CHIPS Act guardrails	None — POET does not receive CHIPS funding	None	N/A
EU Dual-Use Regulation	None — no EU subsidiaries	Medium — EU customer-side compliance burden	N/A
FPI Status	High — could lose FPI status 2026-06-30 or 2027-06-30	N/A — direct compliance-cost impact	Open question

The dominant regulatory variable for POET is (1) China BIS export controls combined with the SPX consolidation and (7) Foreign Private Issuer status renewal. The other regimes either do not apply or apply at the customer-side margin.

7. What to monitor

For the refresh-cycle analyst tracking POET’s regulatory exposure:

BIS Federal Register publications monthly — extensions of the FDPR to optical modules; Entity List additions; advanced-modulator ECCN classifications. Subscribe to the BIS RSS feed at bis.doc.gov.
POET 6-K filings on SPX operational matters — any operational restrictions or supplier issues at SPX would surface here.
Sanan Optoelectronics quarterly disclosures (Shanghai Stock Exchange code 600703) — operational impacts on Sanan IC parent could telegraph SPX supply-chain risk.
SEC FPI-rulemaking docket — track the comments and any rulemaking action on the June-2025 concept release at sec.gov.
Investment Canada Act ministerial reviews — published for major M&A transactions; relevant if POET becomes a takeover target.

The single most-important regulatory signal is any change in the BIS Entity List status of Sanan Optoelectronics or one of POET’s tier-1 module-maker customers. This would be a discrete, datable event — not a slow-moving narrative — and would materially change POET’s investment thesis on the day of disclosure.

Cross-section pointers

jv history — SPX consolidation history; the regulatory exposure flows from this consolidation.
industry dynamics — Customer-landscape detail; explains the Innolight / Eoptolink concentration that drives Risk Pathway A.
tam sam — TAM compression scenarios under regulatory stress.
overview — Geographic-revenue exposure (cross-link).
risks — Bear-case regulatory scenarios pull directly from this file.
overview — Federal Register / EUR-Lex / SAMR primary-source registry.